I think you are referring to dopamine agonists coming up this month vs antimetabolite, which isn’t due for another couple months and not the Prasco deal. I could care less about either of these tiny drugs as they aren’t going to add much value to the company, but will take up mfg utilization. With couple big drugs in pipeline, Elite is being faced with question of slimming down pipeline to delay need for separate mfg location or keep smaller drugs expediting need for more mfg space driving more costs and smaller financial return, but helping diversify portfolio little bit at a time.
News 
Market Data 
Discover 
